COVIA FINAL DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Covia Holdings Corporation f/k/a Fairmount Santrol Holdings Inc. Investors of Important February 8 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – CVIAQ, CVIA, FMSA

NEW YORK, Jan. 23, 2021 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Covia Holdings Corporation f/k/a Fairmount Santrol Holdings Inc. (“Covia”) (OTC: CVIAQ) (NYSE: CVIA) (NYSE: FMSA) between March 15, 2016 and June 29, 2020, inclusive (the “Class Period”), of the important February 8, 2021 lead plaintiff deadline in the first filed securities class action commenced by the firm. The lawsuit seeks to recover damages for Covia investors under the federal securities laws.

To join the Covia class action, go to http://www.rosenlegal.com/cases-register-1993.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Covia’s proprietary “value-added” proppants were not necessarily more effective than ordinary sand; (2) Covia’s revenues, which were dependent on its proprietary “value-added” proppants, was based on misrepresentations; (3) when Covia insiders raised this issue, defendants did not take meaningful steps to rectify the issue; and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 8, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1993.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com



FBIO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Reminds Fortress Biotech, Inc. Investors of Important Tuesday Deadline in Securities Class Action – FBIO

PR Newswire

NEW YORK, Jan. 23, 2021 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and October 9, 2020, inclusive (the “Class Period”), of the important January 26, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Fortress investors under the federal securities laws.

To join the Fortress class action, go to http://www.rosenlegal.com/cases-register-1997.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) intravenous (“IV”) Tramadol was not safe for the intended patient population; (2) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the New Drug Application for IV Tramadol; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 26, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1997.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      cases@rosenlegal.com
      www.rosenlegal.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/fbio-final-deadline-rosen-a-leading-law-firm-reminds-fortress-biotech-inc-investors-of-important-tuesday-deadline-in-securities-class-action–fbio-301213529.html

SOURCE Rosen Law Firm, P.A.

ROSEN, RESPECTED INVESTOR COUNSEL, Reminds QuantumScape Corporation Investors of Important March 8 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – QS

NEW YORK, Jan. 23, 2021 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of QuantumScape Corporation (NYSE: QS) between November 27, 2020 and December 31, 2020, inclusive (the “Class Period”) of the important March 8, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for QuantumScape investors under the federal securities laws.

To join the QuantumScape class action, go to http://www.rosenlegal.com/cases-register-2017.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) QuantumScape’s purported success related to its solid-state battery power, battery life, and energy density were significantly overstated; (2) QuantumScape’s battery technology was not sufficient for electric vehicle performance as it would not be able to withstand the aggressive automotive environment; (3) QuantumScape’s battery technology likely provided no meaningful improvement over existing battery technology; (4) QuantumScape is unlikely to be able to scale its technology to the multi-layer cell necessary to power electric vehicles (5) the successful commercialization of QuantumScape’s battery technology was subject to much more significant risks and uncertainties than defendants had disclosed; and (6) as a result of the foregoing, defendants materially overstated the value and prospects of QuantumScape’s battery technology. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 8, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-2017.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        lrosen@rosenlegal.com
        pkim@rosenlegal.com
        cases@rosenlegal.com
        www.rosenlegal.com



Rosen, Global Investor Counsel, Continues to Investigate Securities Claims Against Exxon Mobil Corporation; Encourages Investors with Losses in Excess of $100K to Contact the Firm – XOM

PR Newswire

NEW YORK, Jan. 23, 2021 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Exxon Mobil Corporation (NYSE: XOM) resulting from allegations that Exxon Mobil may have issued materially misleading business information to the investing public.

On January 15, 2021, TheWall Street Journal published an article titled, “Exxon Draws SEC Probe Over Permian Basin Asset Valuation.” The article reported that the U.S. Securities and Exchange Commission launched an investigation after an Exxon Mobil employee filed a whistleblower complaint alleging that the Company overvalued one if its most important oil and gas properties. The whistleblower complaint asserts that during a 2019 internal assessment, workers were forced to use unrealistic assumptions about how quickly wells in the Permian Basin could be drilled to reach a higher valuation.

On this news, Exxon Mobil’s stock price fell $2.42 per share, or 4.81%, to close at $47.89 per share on January 15, 2021.

Rosen Law Firm is preparing a securities lawsuit on behalf of Exxon Mobil shareholders. If you purchased securities of Exxon Mobil please visit the firm’s website at http://www.rosenlegal.com/cases-register-2021.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      cases@rosenlegal.com
      www.rosenlegal.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-global-investor-counsel-continues-to-investigate-securities-claims-against-exxon-mobil-corporation-encourages-investors-with-losses-in-excess-of-100k-to-contact-the-firm–xom-301213528.html

SOURCE Rosen Law Firm, P.A.

ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Semiconductor Manufacturing International Corporation Investors of Important February 8 Deadline in First Filed Securities Class Action Commenced by the Firm – SMICY

NEW YORK, Jan. 23, 2021 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Semiconductor Manufacturing International Corporation (OTC: SMICY) between April 23, 2020 and September 26, 2020, inclusive (the “Class Period”), of the important February 8, 2021 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for SMIC investors under the federal securities laws.

To join the SMIC class action, go http://www.rosenlegal.com/cases-register-1961.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) there was an “unacceptable risk” that equipment supplied to SMIC would be used for military purposes; (2) SMIC was foreseeably at risk of facing U.S. restrictions; (3) as a result of restrictions by the U.S. Department of Commerce, certain of SMIC’s suppliers would need “difficult-to-obtain” individual export licenses; and (4) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 8, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1961.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        lrosen@rosenlegal.com
        pkim@rosenlegal.com
        cases@rosenlegal.com
        www.rosenlegal.com



BORAL INVESTOR ALERT: Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Boral Limited To Contact Him Directly To Discuss Their Options

NEW YORK, Jan. 23, 2021 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Boral Limited (“Boral” or the “Company”) (Other OTC:BOALY).

If you suffered losses exceeding $50,000 investing in Boral stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/BOALY or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

There is no cost or obligation to you.

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
877.247.4292
212.983.9330
jwilson@faruqilaw.com

On December 5, 2019, Boral revealed that it identified financial irregularities in its North American window business, involving the misreporting of inventory levels and raw material and labor cost at the window plants, and was conducting an internal investigation into the matter.

Then, on February 9, 2020, Boral revealed that its investigation found inflated earnings at its North American window-making business and announced that the Company had fired the division’s vice president of finance and financial controller.

On this news, the Company’s stock price fell from $13.80 per share on February 7, 2020 to $12.72 per share on February 10, 2020: a $1.08 or 7.83% drop.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.



SOLARWINDS DEADLINE ALERT: Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In SolarWinds To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $50,000 investing in SolarWinds stock or options between February 24, 2020 and December 15, 2020 and would like to discuss your legal rights, click here:www.faruqilaw.com/SWI or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

There is no cost or obligation to you.

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
877.247.4292
212.983.9330
jwilson@faruqilaw.com

NEW YORK, Jan. 23, 2021 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against SolarWinds Corporation (“SolarWinds” or the “Company”) (NYSE:SWI) and reminds investors of the March 5, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) since mid-2020, SolarWinds Orion monitoring products had a vulnerability that allowed hackers to compromise the server upon which the products ran; (2) SolarWinds’ update server had an easily accessible password of ‘solarwinds123’; (3) consequently, SolarWinds’ customers, including, among others, the Federal Government, Microsoft, Cisco, and Nvidia, would be vulnerable to hacks; (4) as a result, the Company would suffer significant reputational harm; and (5) as a result, Defendants’ statements about SolarWinds’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Specifically, on December 14, 2020, SolarWinds filed a Form 8-K with the SEC, disclosing that it had been the subject of hack on its Orion monitoring products.

On this news, the Company’s shares fell $3.93 per share, or 17%, to close at $19.62 per share on December 14, 2020, damaging investors.

Then, on December 15, 2020, Reuters published an article stating that, last year, security researcher Vinoth Kumar “alerted the company that anyone could access SolarWinds’ update server by using the password ‘solarwinds123.’” The article also disclosed that, according to Kyle Hanslovan, the cofounder of Maryland-based cybersecurity company Huntress, “days after SolarWinds realized their software had been compromised, the malicious updates were still available for download.”

On this news, the Company’s shares fell $1.56 per share or 8% to close at $18.06 per share on December 15, 2020, damaging investors.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding SolarWinds’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.



ORTHOPEDIATRICS CORPORATION INVESTOR ALERT: Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In OrthoPediatrics Corporation To Contact Him Directly To Discuss Their Options

NEW YORK, Jan. 23, 2021 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential violations of the federal securities laws against OrthoPediatrics Corporation (“OrthoPediatrics or the “Company”) (NASDAQ:KIDS).

If you suffered losses exceeding $50,000 investing in OrthoPediatrics Corporation securities and would like to discuss your legal rights, click here: www.faruqilaw.com/KIDS or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
877.247.4292
212.983.9330
jwilson@faruqilaw.com 

There is no cost or obligation to you.

On December 2, 2020, Culper Research (“Culper”) published a that described OrthoPediatrics Corporation as having “engaged in a channel stuffing scheme that has systematically and significantly overstated revenues.” The Culper report alleged that “the Company has abused its ability to book revenues upon shipment by selling and shipping excess product directly to its distributors, many of whom are exclusive to the Company” and described it as “concerning that many of the Company’s ‘exclusive distributors’ are simply former OrthoPediatrics employees who have formed their own distributorships, often while still employed at the Company.”

On this news, OrthoPediatrics Corporation’s stock price fell $4.12 per share, or 9.13%, to close at $41.02 per share on December 2, 2020.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.



DECISION DIAGNOSTICS DEADLINE ALERT: Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $300,000 In Decision Diagnostics Corp. To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $300,000 investing in Decision Diagnostics stock or options between March 3, 2020 and December 17, 2020 and would like to discuss your legal rights, click here:www.faruqilaw.com/DECN or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

There is no cost or obligation to you.

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
877.247.4292
212.983.9330
jwilson@faruqilaw.com

NEW YORK, Jan. 23, 2021 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Decision Diagnostics Corp. (“Decision Diagnostics” or the “Company”) (Other OTC:DECN) and reminds investors of the March 16, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Decision Diagnostics had not developed any viable COVID-19 test, much less a test that could detect COVID-19 in less than one minute; (2) the Company could not meet the FDA’s emergency use authorization (“EUA”) testing requirements for its purported COVID-19 test; (3) accordingly, Defendants had misrepresented the timeline within which it could realistically bring its COVID-19 test to market; (4) all the foregoing subjected Defendants to an increased risk of regulatory oversight and enforcement; and (5) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Specifically, on December 17, 2020, the Securities and Exchange Commission (“SEC”) filed a complaint in federal court against Defendants, alleging that they had issued a series of press releases that falsely claimed that Decision Diagnostics had developed a finger-prick blood test that could detect COVID-19 in less than one minute (the “SEC Complaint”). According to the SEC Complaint, from March 2020 to at least June 2020, Defendants made false and misleading statements about the existence of Decision Diagnostics’ COVID-19 device and progress towards achieving FDA EUA for that device.  As alleged, at the time of these claims, Decision Diagnostics lacked a proven method for detecting the virus and had no physical testing device.  The SEC Complaint further alleged that the statements created the misleading impression that Decision Diagnostics would soon introduce the COVID-19 test to the market, which led to surges in the price and trading volume of the Company’s stock.

Following the filing of the SEC Complaint, Decision Diagnostics’ common share price fell $0.06 per share, or 60%, to close at $0.04 per share on December 18, 2020.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Decision Diagnostics’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.



SEQUENTIAL BRANDS INVESTOR ALERT: Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sequential Brands To Contact Him Directly To Discuss Their Options

NEW YORK, Jan. 23, 2021 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Sequential Brands Group, Inc. (“Sequential Brands” or the “Company”) (NASDAQ:SQBG).

If you suffered losses exceeding $50,000 investing in Sequential Brands stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/SQBG or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

There is no cost or obligation to you.

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
877.247.4292
212.983.9330
jwilson@faruqilaw.com

On December 11, 2020, the SEC filed a complaint against Sequential Brands alleging the Company failed to timely impair its goodwill as required by generally accepted accounting principles. Specifically, the SEC stated in a press release announcing the lawsuit that “[a]s alleged, by avoiding an impairment to its goodwill in 2016, Sequential inflated its income from operations, created a false impression of its financial condition, and misstated its financial statements and reports for almost a year.” On this news, Sequential Brands stock fell sharply on December 11, 2020.      

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.